Evidence map›Paper›PMID 34001236›Full record

ArticleGenome medicine2021

Integrative statistical analyses of multiple liquid biopsy analytes in metastatic breast cancer.

Corinna Keup, Vinay Suryaprakash, Siegfried Hauch, Markus Storbeck, Peter Hahn, Markus Sprenger-Haussels, Hans-Christian Kolberg, Mitra Tewes, Oliver Hoffmann, Rainer Kimmig and 1 more

Open access · goldAbstract read
In one paragraph

Article in Genome medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 38 citations in OpenAlex.

  1. Review
  2. Review
  3. Liquid Biopsy: The Challenges of a Revolutionary Approach in Oncology.International journal of molecular sciences · 2025
    Review
  4. The diagnostic value of serum exosomal SNORD116 and SNORA21 for NSCLC patients.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Circulating tumor cellsTranslational breast cancer research : a journal focusing on translational research in breast cancer · 2024
    Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Noncoding RNome as Enabling Biomarkers for Precision Health.International journal of molecular sciences · 2022
    Review
  17. New Perspectives on the Importance of Cell-Free DNA Biology.Diagnostics (Basel, Switzerland) · 2022
    Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Corinna KeupDepartment of Gynecology and Obstetrics, University Hospital of Essen, Hufelandstr. 55, 45122, Essen, Germany. corinna.keup@uk-essen.de.ORCID 0000-0003-3525-7511
Vinay SuryaprakashQIAGEN GmbH, 40724, Hilden, Germany.
Siegfried HauchQIAGEN GmbH, 40724, Hilden, Germany.
Markus StorbeckQIAGEN GmbH, 40724, Hilden, Germany.
Peter HahnQIAGEN GmbH, 40724, Hilden, Germany.
Markus Sprenger-HausselsQIAGEN GmbH, 40724, Hilden, Germany.
Hans-Christian KolbergDepartment of Gynecology and Obstetrics, Marienhospital Bottrop, 46236, Bottrop, Germany.
Mitra TewesDepartment of Medical Oncology, University Hospital of Essen, 45122, Essen, Germany.
Oliver HoffmannDepartment of Gynecology and Obstetrics, University Hospital of Essen, Hufelandstr. 55, 45122, Essen, Germany.
Rainer KimmigDepartment of Gynecology and Obstetrics, University Hospital of Essen, Hufelandstr. 55, 45122, Essen, Germany.
Sabine Kasimir-BauerDepartment of Gynecology and Obstetrics, University Hospital of Essen, Hufelandstr. 55, 45122, Essen, Germany.
Essen University Hospital · DEQiagen (Germany) · DEMarienhospital Bottrop · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSingle liquid biopsy analytes (LBAs) have been utilized for therapy selection in metastatic breast cancer (MBC). We performed integrative statistical analyses to examine the clinical relevance of using multiple LBAs: matched circulating tumor cell (CTC) mRNA, CTC genomic DNA (gDNA), extracellular vesicle (EV) mRNA, and cell-free DNA (cfDNA).

methodsBlood was drawn from 26 hormone receptor-positive, HER2-negative MBC patients. CTC mRNA and EV mRNA were analyzed using a multi-marker qPCR. Plasma from CTC-depleted blood was utilized for cfDNA isolation. gDNA from CTCs was isolated from mRNA-depleted CTC lysates. CTC gDNA and cfDNA were analyzed by targeted sequencing. Hierarchical clustering was performed within each analyte, and its results were combined into a score termed Evaluation of multiple Liquid biopsy analytes In Metastatic breast cancer patients All from one blood sample (ELIMA.score), which calculates the contribution of each analyte to the overall survival prediction. Singular value decomposition (SVD), mutual information calculation, k-means clustering, and graph-theoretic analysis were conducted to elucidate the dependence between individual analytes.

resultsA combination of two/three/four LBAs increased the prevalence of patients with actionable signals. Aggregating the results of hierarchical clustering of individual LBAs into the ELIMA.score resulted in a highly significant correlation with overall survival, thereby bolstering evidence for the additive value of using multiple LBAs. Computation of mutual information indicated that none of the LBAs is independent of the others, but the ability of a single LBA to describe the others is rather limited-only CTC gDNA could partially describe the other three LBAs. SVD revealed that the strongest singular vectors originate from all four LBAs, but a majority originated from CTC gDNA. After k-means clustering of patients based on parameters of all four LBAs, the graph-theoretic analysis revealed CTC ERBB2 variants only in patients belonging to one particular cluster.

conclusionsThe additional benefits of using all four LBAs were objectively demonstrated in this pilot study, which also indicated a relative dominance of CTC gDNA over the other LBAs. Consequently, a multi-parametric liquid biopsy approach deconvolutes the genomic and transcriptomic complexity and should be considered in clinical practice.

Indexed as

Biomarkers, TumorLiquid BiopsyBreast NeoplasmsCirculating Tumor DNAClinical Decision-MakingComputational BiologyDisease ManagementDisease SusceptibilityFemaleHigh-Throughput Nucleotide SequencingHumansNeoplastic Cells, CirculatingPrognosisReal-Time Polymerase Chain ReactionSensitivity and SpecificitySequence Analysis, DNABiomarkers, TumorCirculating Tumor DNALiquid biopsyMetastatic breast cancer patientsMulti-analyteMulti-layerMulti-modalMulti-parametric

Identifiers

PMID34001236
PMCPMC8130163
OpenAlexW3160485925

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.